Research by Professor Tin Tin Su, SuviCa’s Co-Founder and CSO, and Dr. Shilpi Verghese, CU Boulder Post-Doctoral Fellow, Published in PLoS Biology

September 2, 2016 By: In: News, Press Releases, Publications Comments Off on Research by Professor Tin Tin Su, SuviCa’s Co-Founder and CSO, and Dr. Shilpi Verghese, CU Boulder Post-Doctoral Fellow, Published in PLoS Biology

Research by Professor Tin Tin Su, SuviCa’s co-founder and CSO, and Dr. Shilpi Verghese, CU Boulder post-doctoral fellow, was published in PLoS Biology in an article titled “Drosophila Wnt and STAT Define Apoptosis-Resistant Epithelial Cells for Tissue Regeneration after Irradiation”. Article Here: http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002536

Read more

SuviCa’s Scientific Advisors Publish Phase 1 Study in Head and Neck Cancer

February 12, 2015 By: In: Press Releases, Publications No Comment

January, 2015:  Congratulations to Drs. Raben and Jimeno who are co-author and senior author, respectively, on an article in Clinical Cancer Research that describes a Phase 1 study of a multi-target inhibitor in combination with chemo-radiation in patients with head and neck cancer. More information at http://www.ncbi.nlm.nih.gov/pubmed/25573383.

Read more

SuviCa, Inc. Awarded SBIR Phase 1 NCI Contract To Study Its Lead Molecules In Preclinical Models Of Head And Neck Cancer

September 26, 2013 By: In: News, Press Releases, Publications No Comment

September 24th, 2013:  SuviCa, Inc., a private cancer drug discovery and development company that applies its proprietary screen to identify small molecule anticancer agents, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract from the National Cancer Institute (NCI).  Through the terms of the contract, SuviCa will discover […]

Read more